Skip to main content
OpenTrials
Completed

NCT Number: NCT01532726

Eslicarbazepine Acetate as Add-On Treatment to One Baseline Antiepileptic Drug (ESLADOBA)

This is a multicenter, non-interventional, prospective study. The observation period comprises at least 6 months, from the initiation of ESL add-on therapy in adult patients with partial-onset epilepsy not sufficiently controlled with one AED, until the first visit that occurs between 6 and 9 months of follow-up. The observation period will end after 9 months of follow-up even if the final assessment is not performed.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital Fernando da Fonseca

Lisbon, Lisbon District, 2720-276, Portugal

About this study

To ensure non-interventional status, the neurologist's decision that it is in the patient's best interest to be prescribed with adjunctive ESL has to be made before and independently of his/her decision to include the patient in the study. At all circumstances during the study the patients will be treated and followed according to routine clinical practice. ESL and concomitant medication should be managed by the neurologist according to the respective Summary of Product Characteristics (SPC).In order to reflect real-life practice and to ensure the observational nature of this study, no fixed time-points for study assessment were defined. Intermediate follow-up data will be collected whenever a patient attends to the study's neurologist consultation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female outpatient, 18 years or older;
  • The patient has an established diagnosis of epilepsy and has experienced at least one partial-onset seizure, with or without secondary generalization, within four weeks prior to initiation of adjunctive ESL;
  • The patient is not sufficiently controlled on a current antiepileptic monotherapy and, in the neurologist clinical judgment, it is in the patient's best interest to be prescribed with adjunctive ESL;
  • The neurologist's decision to prescribe ESL has been made before and independently of his/her decision to include the patient in this study;
  • The patient's treatment is in accordance with the SPC of ESL;
  • Written informed consent from the patient (or legally acceptable representative, if the subject is unable to provide informed consent).

Exclusion criteria

  • Known hypersensitivity to the active substance, carboxamide derivatives (e.g. oxcarbazepine or carbamazepine) or to any of its excipients;
  • Patient with 2nd or 3rd degree atrioventricular block;
  • Patient treated with an experimental drug within four weeks prior to the introduction of ESL;
  • Female patient who is pregnant, lactating, or who is planning to become pregnant during the study period;
  • Patient starting ESL outside the approved SPC at enrolment.

Treatment and study plan

ESL

Drug

ESL 400/800/1200 mg tablets once daily

Other names: Zebinix

Primary outcomes

  1. ESL retention rate

    Time frame: 9 months

    Proportion of patients on ESL treatment at the final assessment

Secondary outcomes

  1. CGI-C score at the final assessment.

    Time frame: 9 monthss

    Assessment of effectivenes

  2. Changes in CGI-S score from baseline to final assessment

    Time frame: 9 months

    Assessment of effectivenes

  3. CGI-Efficacy Index scores at the final assessment

    Time frame: 9 months

    Assessment of effectivenes

  4. Proportion of patients who are responders to ESL (at least 50% reduction in seizure frequency) at the final assessment

    Time frame: 9 months

    Assessment of effectivenes

  5. Proportion of seizure-free patients within the 12 weeks prior to final assessment

    Time frame: 9 months

    Assessment of effectivenes

  6. Proportion of seizure-free patients within the 4 weeks prior to final assessment

    Time frame: 9 months

    Assessment of effectivenes

  7. Changes in seizure frequency for partial seizures with or without secondary generalization, from baseline to final assessment

    Time frame: 9 months

    Assessment of effectivenes

  8. Changes in seizure frequency for partial seizures without secondary generalization, from baseline to final assessment

    Time frame: 9 months

    Assessment of effectivenes

  9. Changes in seizure frequency for partial seizures with secondary generalization, from baseline to final assessment

    Time frame: 9 months

    Assessment of effectivenes

  10. Changes in QOLIE-10-P scores from baseline to final assessment

    Time frame: 9 months

    assessment of Quality of life

  11. Occurrence of AEs during the study (overall and treatment-related)

    Time frame: 9 months

    assessment of Adverse Events

Sponsors and collaborators

Lead sponsor

Bial - Portela C S.A.

Industry

Registry information

Official study title

A Non-Interventional, Prospective Study to Assess Seizure Control and Tolerability of Eslicarbazepine Acetate as Adjunctive Therapy to One Baseline Antiepileptic Drug, in Adults With Partial-Onset Seizures With or Without Secondary Generalization

Important dates

Study start
2012
Primary completion
2014
Study completion
2014
First posted
Feb 14, 2012
Registry last updated
Jan 6, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.